Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Molecular cancer therapeutics - 1 Oct 2021

Adashek Jacob J, Desai Aakash P, Andreev-Drakhlin Alexander Y, Roszik Jason, Cote Gilbert J, Subbiah Vivek

Abstract excerpt

Activating receptor-tyrosine kinase rearranged during transfection (RET) mutations and fusions are potent drivers of oncogenesis. The recent FDA approvals of highly potent and selective RET inhibitors, selpercatinib and pralsetinib, has altered the therapeutic management of RET aberrant tumors. There is ample evidence of the role of RET signaling in certain cancers. RET aberrations as fusions or mutations occur...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Neoplasms

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Source

Open in PubMed Open full text

Identifiers

PMID: 34493590
DOI: 10.1158/1535-7163.MCT-21-0329
PMCID: PMC8492504

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.PMID 34493590Read ↗

RET signaling pathway and RET inhibitors in human cancerSemantic proximity Read ↗

Progresses Toward Precision Medicine in RET-altered Solid Tumors.Semantic proximity Read ↗

Precision oncology for RET-related tumorsSemantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

REToma: a cancer subtype with a shared driver oncogene.Semantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.Semantic proximity Read ↗

A comprehensive overview of the relationship between RET gene and tumor occurrenceSemantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.